Answers are grounded in this paper and cite their sources.
Aim: The aim of the present study is to assess the effi cacy and safety of Hydroxychloroquine in comparison with Teneligliptin in type 2 diabetes patients whose blood glucose levels were inadequately controlled with metformin, Glimepiride and insulin therapy. Methods: This was a randomized, prospective, parallel-group, experimental trial done in 300 Type 2 Diabetes patients who were uncontrolled (HbA1c=7.5–10%) with metformin, Glimepiride and insulin therapy. Patients were randomly divided into two groups one received Teneligliptin 20 mg (n=152) and other received Hydroxychloroquine 400 mg (n=148) while continuing insulin therapy with other 2 OHA. Insulin doses were adjusted to maintain normal blood glucose levels. Result: The adjusted mean change from baseline to endpoint in HbA1c was −1.2±0.5% in patient group receiving Hydroxychloroquine and −0.9±0.5% in patients group receiving Teneligliptin, respectively, with a signifi cant between-treatment difference (p<0.001). The incidence of adverse events was similar in the Hydroxychloroquine (72%) and Teneligliptin (77%) groups. However, hypoglycaemic events were less common (p<0.001) and less severe (p<0.05) in patients receiving Hydroxychloroquine than in those receiving Teneligliptin. Conclusion: Hydroxychloroquine decreases HbA1c in patients whose type 2 diabetes is poorly controlled with high doses of insulin as compare to Teneligliptin. Addition of hydroxychloroquine to insulin therapy is also associated with reduced incidence of confi rmed and severe hypoglycaemia. Research Article Comparison of Effi cacy and Safety of Hydroxychloroquine and Teneligliptin in Type 2 Diabetes Patients who are Inadequately Controlled with Glimepiride, Metformin and Insulin therapy: A Randomized Controlled Trial with Parallel Group Design Prakash Ranjan1, Sajjad Ahsan2*, Rabi Bhushan1, Bipin Kumar3, Tushar4, Anup Kumar Gupta1, Anand Kumar Verma1 and Mukesh Jain1 1The National Institute of Health and Family Welfare, New Delhi, India 2Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India 3Patna Medical College and Hospital, Patna, Bihar, India 4Darbhanga Medical College and Hospital, Darbhanga, Bihar, India *Address for Correspondence: Dr. Sajjad Ahsan, Department of Endocrinology, Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India, Email: sajjad.ahsan@rediffmail.com Submitted: 29 August 2018 Approved: 12 September 2018 Published: 13 September 2018 Copyright: © 2018 Ranjan P, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
No takes yet. Share an insight, caveat, or question.
Sajjad Ahsan (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: